Drug2ways: Reasoning over causal paths in biological networks for drug discovery

Elucidating the causal mechanisms responsible for disease can reveal potential therapeutic targets for pharmacological intervention and, accordingly, guide drug repositioning and discovery. In essence, the topology of a network can reveal the impact a drug candidate may have on a given biological state, leading the way for enhanced disease characterization and the design of advanced therapies. Network-based approaches, in particular, are highly suited for these purposes as they hold the capacity to identify the molecular mechanisms underlying disease. Here, we present drug2ways, a novel methodology that leverages multimodal causal networks for predicting drug candidates. Drug2ways implements an efficient algorithm which reasons over causal paths in large-scale biological networks to propose drug candidates for a given disease. We validate our approach using clinical trial information and demonstrate how drug2ways can be used for multiple applications to identify: i) single-target drug candidates, ii) candidates with polypharmacological properties that can optimize multiple targets, and iii) candidates for combination therapy. Finally, we make drug2ways available to the scientific community as a Python package that enables conducting these applications on multiple standard network formats.

[1]  L. Kwong,et al.  Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models , 2016, Oncotarget.

[2]  Jan Baumbach,et al.  From single drug targets to synergistic network pharmacology in ischemic stroke , 2019, Proceedings of the National Academy of Sciences.

[3]  Taro Kishi,et al.  Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2014, Alzheimer's & Dementia.

[4]  Andrea Rocca,et al.  Progress with palbociclib in breast cancer: latest evidence and clinical considerations , 2017, Therapeutic advances in medical oncology.

[5]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[6]  Benjamin J. Raphael,et al.  Network propagation: a universal amplifier of genetic associations , 2017, Nature Reviews Genetics.

[7]  Min Yi,et al.  CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers , 2017, Nature Communications.

[8]  Emanuel F. Petricoin,et al.  The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma , 2017, Oncotarget.

[9]  Daniel Blankenberg,et al.  Software engineering for scientific big data analysis , 2019, GigaScience.

[10]  Marco Roos,et al.  Drug prioritization using the semantic properties of a knowledge graph , 2019, Scientific Reports.

[11]  Gemma C. Garriga,et al.  Randomization Techniques for Graphs , 2009, SDM.

[12]  Ping Wang,et al.  Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo , 2016, Clinical Cancer Research.

[13]  Sharon Munn,et al.  Adverse outcome pathway networks II: Network analytics , 2018, Environmental toxicology and chemistry.

[14]  Charles Auffray,et al.  Navigating the disease landscape: knowledge representations for contextualizing molecular signatures , 2018, Briefings Bioinform..

[15]  Ewold Verhagen,et al.  Nonlinear cavity optomechanics with nanomechanical thermal fluctuations , 2016, Nature Communications.

[16]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[17]  Sebastian F Salathe,et al.  Losartan Rescues Inflammation-Related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis. , 2020, American journal of respiratory and critical care medicine.

[18]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[19]  Ryan Miller,et al.  WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research , 2017, Nucleic Acids Res..

[20]  Peter A. Flach,et al.  Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them) , 2012, Briefings Bioinform..

[21]  A. Barabasi,et al.  Predicting perturbation patterns from the topology of biological networks , 2018, Proceedings of the National Academy of Sciences.

[22]  Aurélien Naldi,et al.  Decision Diagrams for the Representation and Analysis of Logical Models of Genetic Networks , 2007, CMSB.

[23]  S. Kauffman Metabolic stability and epigenesis in randomly constructed genetic nets. , 1969, Journal of theoretical biology.

[24]  Ruth Nussinov,et al.  Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.

[25]  Evan O. Paull,et al.  Inferring causal molecular networks: empirical assessment through a community-based effort , 2016, Nature Methods.

[26]  Aki Vehtari,et al.  An additive Gaussian process regression model for interpretable non-parametric analysis of longitudinal data , 2019, Nature Communications.

[27]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[28]  Christian Staudt,et al.  NetworKit: A tool suite for large-scale complex network analysis , 2014, Network Science.

[29]  Michael R Knowles,et al.  AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[30]  Gary D Bader,et al.  Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap , 2019, Nature Protocols.

[31]  Doheon Lee,et al.  Annotating activation/inhibition relationships to protein-protein interactions using gene ontology relations , 2018, BMC Systems Biology.

[32]  Kara Dolinski,et al.  The BioGRID interaction database: 2019 update , 2018, Nucleic Acids Res..

[33]  Rafael C. Jimenez,et al.  The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases , 2013, Nucleic Acids Res..

[34]  Tong Xi,et al.  One-year postoperative skeletal stability of 3D planned bimaxillary osteotomies: maxilla-first versus mandible-first surgery , 2019, Scientific Reports.

[35]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[36]  Edward R. Dougherty,et al.  Probabilistic Boolean networks: a rule-based uncertainty model for gene regulatory networks , 2002, Bioinform..

[37]  P. Aloy,et al.  Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer. , 2017, Cancer research.

[38]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[39]  Reinhard Schneider,et al.  Using graph theory to analyze biological networks , 2011, BioData Mining.

[40]  Shih-Heng Yeh,et al.  A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer , 2012, Journal of Clinical Bioinformatics.

[41]  Martin Hofmann-Apitius,et al.  PathMe: merging and exploring mechanistic pathway knowledge , 2018, BMC Bioinformatics.

[42]  Aric Hagberg,et al.  Exploring Network Structure, Dynamics, and Function using NetworkX , 2008, Proceedings of the Python in Science Conference.

[43]  A. Barabasi,et al.  Network-based in silico drug efficacy screening , 2016, Nature Communications.

[44]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.

[45]  Corrado Priami,et al.  A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome , 2019, Nature Communications.

[46]  Byung-Gee Kim,et al.  Genome-scale model-driven strain design for dicarboxylic acid production in Yarrowia lipolytica , 2018, BMC Systems Biology.

[47]  Albert-László Barabási,et al.  Publisher Correction: Network-based prediction of drug combinations , 2019, Nature Communications.

[48]  Shinji Takeuchi,et al.  Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report , 2020, BMC Cancer.